Fluzone + Pneumovax 23

This entry refers to the co-administration of the influenza vaccine (Fluzone) and the 23-valent pneumococcal polysaccharide vaccine (Pneumovax 23). This specific combination was studied by the University of Alabama at Birmingham to evaluate B-lymphocyte stimulator (BLyS) and interferon (IFN) responses in patients with Systemic Lupus Erythematosus (SLE) compared to healthy controls. Fluzone is an inactivated influenza vaccine designed to provide protection against seasonal flu by inducing antibodies against viral hemagglutinin. Pneumovax 23 is a polyvalent vaccine containing capsular polysaccharides from 23 serotypes of Streptococcus pneumoniae, providing active immunization against pneumococcal disease. Both vaccines are widely approved for their respective indications and were used as an antigen challenge in the context of autoimmune research.

Brand names

FluzonePneumovax 23Pneumovax23Pneumovax-23

Other names

Influenza vaccine + Pneumococcal vaccine polyvalent